ArticleCancer genomics & proteomics
Reprogramming-driven Proteomic Shifts Mirror Bladder Cancer Progression and Reveal Biomarker Candidates Across Disease Grades.
Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe acquisition of stem-like properties and increased cellular plasticity is thought to drive tumor progression and therapeutic resistance, but grade-specific molecular trajectories across the epigenetic landscape in bladder cancer remain poorly defined. This study examined the dynamic rewiring of signaling networks and proteomic landscapes during reprogramming of low-grade (HTB-2) and high-grade (HTB-5) bladder cancer cells, and during their subsequent differentiation into embryoid bodies. MATERIALS AND
methodsSix experimental models were analyzed, including the parental HTB-2 and HTB-5 cells, their Sendai virus-reprogrammed counterparts (rep HTB-2 and rep HTB-5) and embryoid bodies generated from reprogrammed derivatives (rep HTB-2 EB and rep HTB-5 EB), with SV-HUC-1 uroepithelial cells used as a control. Phosphoproteomic and integrated proteomic analyses were performed to define grade-specific signaling architectures and shared plasticity-associated signatures, followed by clinical validation using pan-cancer datasets.
resultsPhosphoproteomic reconstruction revealed grade-dependent kinase network architectures associated with stem-like induction. These findings indicate that reprogramming induced cell-line-specific signaling rewiring, with HTB-2 cells showing enhanced MAPK/Src-family-associated phosphorylation and HTB-5 cells showing increased AKT/PRAS40 and STAT1/STAT3 phosphorylation together with reduced ERK1/2-MSK1/2 signaling. During differentiation, low-grade cells underwent metabolic reprogramming, while high-grade cells favored cytoskeletal remodeling and extracellular matrix organization. Integrated proteomics defined a shared plasticity signature, with reprogrammed models recapitulated key bladder cancer features and clinically relevant outcomes.
conclusionThese findings support a hierarchical model of bladder cancer progression where reprogramming induces a transient intermediate state that enables invasive features upon re-differentiation. The study reveals grade-specific signaling and proteomic adaptations, identifying differentiation as a critical window for uncovering prognostic biomarkers and therapeutic targets. Together, these results suggest that reprogrammed bladder cancer models provide a biologically relevant platform to study tumor plasticity, progression and therapeutic vulnerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.